Marco Santonico Selected Research

Electronic Nose

9/2020	Characterization of inflammatory profile by breath analysis in chronic coronary syndromes.
1/2019	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma.
1/2018	Validation of exhaled volatile organic compounds analysis using electronic nose as index of COPD severity.
1/2018	Breathprinting and Early Diagnosis of Lung Cancer.
1/2017	Screening of Obstructive Sleep Apnea Syndrome by Electronic-Nose Analysis of Volatile Organic Compounds.
4/2016	BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes†.
2/2016	Volatile signature for the early diagnosis of lung cancer.
1/2016	Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study.
11/2015	The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs.
1/2015	Exhaled breath analysis by electronic nose in respiratory diseases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marco Santonico Research Topics

Disease

5	Lung Neoplasms (Lung Cancer) 01/2018 - 05/2010
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2018 - 01/2012
2	Asthma (Bronchial Asthma) 01/2019 - 04/2010
2	Lung Diseases (Lung Disease) 01/2019 - 01/2017
2	Obstructive Sleep Apnea 01/2017 - 05/2015
2	Neoplasms (Cancer) 11/2015 - 05/2012
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2015 - 01/2012
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2021
1	Diverticular Diseases 01/2021
1	Dysbiosis 01/2021
1	Heart Failure 09/2020
1	Infections 01/2020
1	Pleural Effusion (Pleural Effusions) 01/2020
1	Ascites 01/2020
1	Portal Hypertension 01/2020
1	Fibrosis (Cirrhosis) 01/2017
1	Liver Diseases (Liver Disease) 01/2016
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016
1	Halitosis 03/2008

Drug/Important Bio-Agent (IBA)

7	Volatile Organic CompoundsIBA 01/2018 - 05/2015
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2017
2	GoldIBA 01/2018 - 01/2012
1	diazonaphthalenedisulfonic acid (NDS)IBA 05/2021
1	Rifaximin (L 105)FDA Link 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Biological ProductsIBA 01/2020
1	AlbuminsIBA 01/2020
1	SteroidsIBA 01/2019
1	SolutionsIBA 05/2012
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2010
1	n-pentanoic acid (valeric acid)IBA 03/2008
1	QuartzIBA 03/2008
1	Butyric Acid (Butanoic Acid)IBA 03/2008
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 03/2008

Therapy/Procedure

15	Electronic Nose 09/2020 - 03/2008
3	Therapeutics 01/2021 - 04/2014
1	Noninvasive Ventilation 05/2015
1	Continuous Positive Airway Pressure 05/2015